Drugs & Targets HOOKIPA, Roche form collaboration to develop arenaviral immunotherapy for KRAS-mutated cancers October 21, 2022Vol.48 No.38
Drugs & Targets Jazz Pharmaceuticals and Zymeworks agree to develop, commercialize zanidatamab October 21, 2022Vol.48 No.38
Drugs & Targets Health Canada approves Merck’s Keytruda as post-surgery monotherapy in kidney cancer patients October 14, 2022Vol.48 No.37
Drugs & Targets Eclipse and Mayo create Nucleus RadioPharma to improve radiopharmaceutical manufacturing October 14, 2022Vol.48 No.37
Drugs & Targets FDA grants accelerated approval to Lytgobi for cholangiocarcinoma October 07, 2022Vol.48 No.36
Drugs & Targets MD Anderson and ARTIDIS form strategic alliance to advance nanomechanical technology platform October 07, 2022Vol.48 No.36
Drugs & Targets Merck’s Keytruda receives four approvals in Japan, including in high-risk early-stage TNBC September 30, 2022Vol.48 No.35
Drugs & Targets FDA approves Retevmo for locally advanced or metastatic RET fusion-positive solid tumors, NSCLC September 23, 2022Vol.48 No.34
Drugs & Targets FDA approves Pedmark to reduce the risk of ototoxicity associated with cisplatin for localized pediatric solid tumors September 23, 2022Vol.48 No.34
